KUMAMOTO University

R

研究業績RESEARCH ACHIEVEMENTS

  1. Kusumoto S, Tanaka Y, Suzuki R, Watanabe T, Nakata M, Sakai R, Fukushima N, Fukushima T, Moriuchi Y, Itoh K, Nosaka K, Choi I, Sawa M, Okamoto R, Tsujimura H, Uchida T, Suzuki S, Okamoto M, Takahashi T, Sugiura I, Onishi Y, Kohri M, Yoshida S, Kojima M, Takahashi H, Tomita A, Atsuta Y, Maruyama D, Tanaka E, Suzuki T, Kinoshita T, Ogura M, Ueda R and Mizokami M.

    Ultra-high sensitivity HBsAg assay can diagnose HBV reactivation following rituximab-based therapy in patients with lymphoma.

    J Hepatol 73(2):285-293,2020.  doi: 10.1016/j.jhep.2020.03.009. Epub 2020 Mar 17.

    https://pubmed.ncbi.nlm.nih.gov/32194183/

     

  2. Utsunomiya M, Dobashi H, Odani T, Saito K, Yokogawa N, Nagasaka K, Takenaka K, Soejima M, Sugihara T, Hagiyama H,Hirata S, Matsui K, Nonomura Y, Kondo M, Suzuki F, Nawata Y, Tomita M, Kihara M, Yokoyama-Kokuryo W, Hirano F, Yamazaki H, Sakai R, Nanki T, Koike R, Miyasaka N, Harigai M.

    An open-label, randomized controlled trial of sulfamethoxazole-trimethoprim for Pneumocystis prophylaxis: results of 52-week follow-up.

    Rheumatol Adv Pract 4(2):rkaa029,2020.  doi: 10.1093/rap/rkaa029. eCollection 2020

    https://pubmed.ncbi.nlm.nih.gov/33134810/

     

     

  3. Murata M, Yasunaga JI, Washizaki A, Seki Y, Kuramitsu M, Tan WK, Hu A, Okuma K, Hamaguchi I, Mizukami T, Matsuoka M, Araki H

    Frequent horizontal and mother-to-child transmission may contribute to high prevalence of STLV-1 infection in Japanese macaques.

    Retrovirology 17(1):15,2020. doi: 10.1186/s12977-020-00525-1.

    https://pubmed.ncbi.nlm.nih.gov/32576215/

     

  4. Higuchi Y, Yasunaga JI, Mitagami Y, Tsukamoto H, Nakashima K, Ohshima K, Matsuoka M.

    HTLV-1 induces T cell malignancy and inflammation by viral antisense factor-mediated modulation of the cytokine signaling.

    Proc Natl Acad Sci U S A. 2020 Jun 16;117(24):13740-13749. doi: 10.1073/pnas.1922884117. Epub 2020 May 29.

    https://pubmed.ncbi.nlm.nih.gov/32471947/

     

     

  5. Sakurai M, Okamoto S, Matsumura I, Murakami S, Takizawa M, Waki M, Hirano D, Watanabe-Nakaseko R, Kobayashi N, Iino M, Mitsui H, Ishikawa Y, Takahashi N, Kawaguchi T, Suzuki R, Yamamoto K, Kizaki M, Ohnishi K, Naoe T, Akashi K.

    New Target investigators. Treatment outcomes of chronic-phase chronic myeloid leukemia with resistance and/or intolerance to a 1st-line tyrosine kinase inhibitor in Japan: the results of the New TARGET study 2nd-line.

    Int J Hematol 111 (6): 812-825,2020. doi: 10.1007/s12185-020-02843-8. Epub 2020 Mar 9.

    https://pubmed.ncbi.nlm.nih.gov/32152876/

     

  6. Makita S, Maruyama D, Maeshima AM, Taniguchi H, Yuda S, Toyoda K, Yamauchi N, Fukuhara S, Munakata W, Kobayashi Y, Kurihara H, Izutsu K and Tobinai K.

    A comparison of clinical staging using the Lugano versus Ann Arbor classifications in Japanese patients with Hodgkin lymphoma.

    Asia Pac J Clin Oncol 16(3):108-114,2020.  doi: 10.1111/ajco.13248. Epub 2019 Dec 4.

    https://pubmed.ncbi.nlm.nih.gov/31802636/

     

  7. Kuriyama H, Fukushima S, Nakahara S, Kanemaru H, Miyashita A, Aoi J, Tomita Y, Kawasaki T, Nosaka K and Ihn H.

    Serious disseminated intravascular coagulation associated with combination therapy of nivolumab and ipilimumab in advanced melanoma.

    J Dermatol 47(6):e235-e237,2020. doi: 10.1111/1346-8138.15336. Epub 2020 Apr 10.

    https://pubmed.ncbi.nlm.nih.gov/32275077/

     

  8. Nosaka K and Matsuoka M

    Adult T-cell leukemia-lymphoma as a viral disease: subtypes based on viral aspects.

    ancer Sci ,112(5):1688-1694. doi: 10.1111/cas.14869. Epub 2021 Mar 30.

    https://pubmed.ncbi.nlm.nih.gov/33630351/

     

     

  9. Yasunaga JI.

    Strategies of Human T-Cell Leukemia Virus Type 1 for Persistent Infection: Implications for Leukemogenesis of Adult T-Cell Leukemia-Lymphoma.

    Front Microbiol 19;11:979,2020. 5.19 doi: 10.3389/fmicb.2020.00979.

    https://pubmed.ncbi.nlm.nih.gov/32508789/

     

  10. Ghosh AK, Kovela S, Osswald HL, Amano M, Aoki M, Agniswamy J, Wang YF, Weber IT, Mitsuya H.
    Structure-Based Design of Highly Potent HIV-1 Protease Inhibitors Containing New Tricyclic Ring P2-Ligands: Design, Synthesis, Biological, and X-ray Structural Studies.
    J Med Chem. 2020 May 14;63(9):4867-4879. doi: 10.1021/acs.jmedchem.0c00202. PMID: 32348139; PMCID: PMC7425579

  11. Oda K, Katonoda T, Hashiguchi Y, Kondo S, Narita Y, Iwamura K, Nosaka K, Jono H and Saito H.

    Development and evaluation of a vancomycin dosing nomogram to achieve the target area under the concentration-time curve. A retrospective study.

    J Infect Chemother 26(5):444-450,2020. doi: 10.1016/j.jiac.2019.11.009. Epub 2019 Dec 24.

    https://pubmed.ncbi.nlm.nih.gov/31879186/

     

  12. Oda K, Miyakawa T, Katanoda T, Hashiguchi Y, Iwamura K, Nosaka K, Yamaguchi A, Jono H and Saito H.

    A case of recovery from aphasia following dose reduction of cefepime by bayesian prediction-based therapeutic drug monitoring.

    J Infect Chemother 26(5):498-501,2020. doi: 10.1016/j.jiac.2019.10.006. Epub 2020 Mar 4.

    https://pubmed.ncbi.nlm.nih.gov/32143960/

     

  13. Maeda M, Tanabe-Shibuya J, Miyazato P, Masutani H, Yasunaga JI, Usami K, Shimizu A, Matsuoka M.

    IL-2/IL-2 Receptor Pathway Plays a Crucial Role in the Growth and Malignant Transformation of HTLV-1-Infected T Cells to Develop Adult T-Cell Leukemia.

    Front Microbiol. 2020 Mar 6;11:356. doi: 10.3389/fmicb.2020.00356. eCollection 2020.

    https://pubmed.ncbi.nlm.nih.gov/32210945/

     

  14. Fuji S, Kurosawa S, Inamoto Y, Murata T, Utsunomiya A, Uchimaru K, Yamasaki S, Inoue Y, Moriuchi Y, Choi I, Ogata M, Hidaka M, Yamaguchi T, Fukuda T.

    A decision analysis comparing unrelated bone marrow transplantation and cord blood transplantation in patients with aggressive adult T-cell leukemia-lymphoma.

    Int J Hematol 111(3):427-433,2020. doi: 10.1007/s12185-019-02777-w. Epub 2019 Nov 7.

    https://pubmed.ncbi.nlm.nih.gov/31701480/

     

  15. Shichijo T, Fuji S, Nagler A, Bazarbachi A, Mohty M, Savani BN.

    Personalizing rabbit anti-thymocyte globulin therapy for prevention of graft-versus-host disease after allogeneic hematopoietic cell transplantation: is there an optimal dose?

    Bone Marrow Transplant 55(3): 505-522,2020.doi: 10.1038/s41409-019-0643-9. Epub 2019 Aug 21.

    https://pubmed.ncbi.nlm.nih.gov/31435032/

     

  16. Cui G, Shimba A, Ma G, Takahara K, Tani-Ichi S, Zhu Y, Asahi T, Abe A, Miyachi H, Kitano S, Hara T, Yasunaga JI, Suwanai H, Yamada H, Matsuoka M, Ueki K, Yoshikai Y, Ikuta K.

    IL-7R-Dependent Phosphatidylinositol 3-Kinase Competes with the STAT5 Signal to Modulate T Cell Development and Homeostasis.

    J Immunol. 2020 Feb 15;204(4):844-857. doi: 10.4049/jimmunol.1900456. Epub 2020 Jan 10.

    https://pubmed.ncbi.nlm.nih.gov/31924648/

     

  17. Nishimura N, Endo S, Kawano Y.

    Myeloma Mouse Models in Studying Myeloma Associated Bone Disease.

    Encyclopedia of Bone Biology 3:355-361,2020.

     

     

     

  18. Nagafuji K, Matsumura I, Shimose T, Kawaguchi T, Kuroda J, Nakamae H, Miyamoto T, Kadowaki N, Ishikawa J, Imamura Y, Yamazaki H, Akashi K, Kanakura Y.

    Cessation of nilotinib in patients with chronic myelogenous leukemia who have maintained deep molecular responses for 2 years: a multicenter phase 2 trial, stop nilotinib (NILSt).

    Int J Hematol .2019 Dec;110(6):675-682. doi: 10.1007/s12185-019-02736-5. PMID: 31538327

  19. Shirayama R, Takedani H, Chikasawa Y, Ishiguro A, Ishimura M, Isobe K, Uchiba M, Ogata Y, Kakuda H, Kusuhara K, Shirahata A.

    Perioperative safety and haematostatic efficacy of a new bypassing agent pd-FVIIa/FX (Byclot) in haemophilia patients with high-responding type inhibitors.

    Blood Coagul Fibrinolysis.2019 Dec;30(8):385-392. doi: 10.1097/MBC.0000000000000851. PMID: 31738288

  20. Ishikawa M, Iriyama N, Tokuhira M, Takaku T, Sato E, Sugimoto K J, Nakazato T, Fujita H, Kimura Y, Fujioka I, Komatsu N, Asou N, Kizaki M, Hatta Y, Kawaguchi T.

    Potential role for secondgeneration tyrosine kinase inhibitors in patients with chronic myeloid leukemia harboring additional clonal chromosome abnormalities: A retrospective CML Cooperative Study Group analysis.

    Oncol Rep.2019 Dec;42(6):2836-2843. doi: 10.3892/or.2019.7339. Epub 2019 Sep 27. PMID: 31578586

  21. Takenaka K, Minami T, Yoshihashi Y, Hirata S, Kimura Y, Kono H.

    Decrease in MPO-ANCA after administration of benralizumab in eosinophilic granulomatosis with polyangiitis.

    Allergol Int.2019 Oct;68(4):539-540. doi: 10.1016/j.alit.2019.04.006. Epub 2019 May 9. PMID: 31080020

  22. Nishimura N, Radwan MO, Amano M, Endo S, Fujii E, Hayashi H, Ueno S, Ueno N, Tatetsu H, Hata H, Okamoto Y, Otsuka M, Mitsuya H, Matsuoka M, Okuno Y.

    Novel p97/VCP inhibitor induces endoplasmic reticulum stress and apoptosis in both bortezomib-sensitive and -resistant multiple myeloma cells.

    Cancer Sci. 2019 Oct;110(10):3275-3287. doi: 10.1111/cas.14154. Epub 2019 Aug 14. PMID: 31368616; PMCID: PMC6778635.

    https://pubmed.ncbi.nlm.nih.gov/31368616/

     

  23. Onitsuka K, Tokuda R, Kuwata-Higashi N, Kumamoto H, Aoki M, Amano M, Kohgo S, Das D, Haraguchi K, Mitsuya H, Imoto S.

    Synthesis and evaluation of the anti-hepatitis B virus activity of 4′-Azido-thymidine analogs and 4′-Azido-2′-deoxy-5-methylcytidine analogs: structural insights for the development of a novel anti-HBV agent.

    Nucleosides Nucleotides Nucleic Acids. 2019 Sep 12;1-12. doi: 10.1080/15257770.2019.1664749. [Epub ahead of print]. PMID: 31514570.

    https://pubmed.ncbi.nlm.nih.gov/31514570/

  24. Noyori O, Komohara Y, Nasser H, Hiyoshi M, Ma C, Pan C, Carreras J, Nakamura N, Sato A, Ando K, Okuno Y, Nosaka K, Matsuoka M, and Suzu S.

    Expression of IL-34 correlates with macrophage infiltration and prognosis of diffuse large B-cell lymphoma.

    Clin Transl Immunology.2019 Aug 13;8(8):e1074. doi: 10.1002/cti2.1074. eCollection 2019. PMID: 31417675

    https://pubmed.ncbi.nlm.nih.gov/31417675/

     

CONTACT US

C

  • 患者様へ

    外来診療の方は外来予約センターより
    ご予約をお願いいたします。
    外来予約センター

  • 学生・研修医・医療関係者の方へ

    TEL
    096-373-5156
    FAX
    096-373-5158
    Mail
    nikyo*kumamoto-u.ac.jp
    (*はアットマーク)
Copyright 2019 KUMAMOTO University HRI All Rights Reserved.